Table 5 Characteristics of the study sample, categorized by SRI tertiles

Variable

1st SRI % Tertile

(≤ 47.06)

(n = 48)

2nd SRI % Tertile

(47.06–78.18)

(n = 52)

3rd SRI % Tertile

(> 78.18)

(n = 49)

P value

Age^a

64.31 (±12.18)

63.5 (55.25 – 71)

59.08 (±10.24)

60.5 (54.25 – 65)

57.12 (±11.93)

58 (49.5 – 64)

0.007*

Sex^a

Male: 31 (64.6%)

Male: 36 (69.2%)

Male: 35 (71.4%)

0.8

BMI^a

27.48 (±4.84)

26.9 (24.3 – 29.4)

27.903 (±3.87)

27.7 (24.95 – 29.4)

28.05 (±4.7)

27.7 (24.5 – 29.7)

0.9

Dyslipidemia^b

27 (56.3%)

33 (63.5%)

23 (46.9%)

0.2

Smoking^b

18 (37.5%)

25 (48.1%)

24 (49%)

0.6

Hypertension^b

22 (45.8%)

23 (44.2%)

22 (44.9%)

0.99

Diabetes^b

15 (31.3%)

20 (38.5%)

17 (34.7%)

0.8

Pain to Presentation Time (Hours)^a

7.29 (± 6.11)

6 (4 – 7.75)

5.89 (± 4.13)

5.5 (2 – 9.75)

7.86 (± 7.45)

5 (3 – 12)

0.6

STEMI/NSTEMI^b

38 (79.2%)/10 (21.8%)

45 (86.5%)/7 (13.5%)

34 (69.4%)/15 (30.6%)

0.1

ST Resolution^b

(n = 117)

N/A: 4 (10.5%)

< 30%: 4 (10.5%)

30 – 70%: 25 (65.8%)

> 70%: 5 (13.2%)

(n = 38)

N/A: 1 (2.2%)

< 30%: 4 (8.9%)

30 – 70%: 25 (55.6%)

> 70%: 15 (33.3%)

(n = 45)

N/A: 2 (5.9%)

< 30%: 2 (5.9%)

30 – 70%: 20 (58.8%)

> 70%: 10 (29.4%)

(n = 34)

0.4

Significant ST Resolution^b (n = 117)

30 (78.9%)

40 (88.9%)

30 (88.2%)

0.4

KILLIP Classification^b

Class I: 43 (89.6%)

Class II: 1 (2.1%)

Class III: 0 (0%)

Class IV: 4 (8.3%)

Class I: 41 (78.8%)

Class II: 10 (19.2%)

Class III: 0 (0%)

Class IV: 1 (1.9%)

Class I: 41 (83.7%)

Class II: 4 (8.2%)

Class III: 2 (4.1%)

Class IV: 2 (4.1%)

0.017*

Ejection Fraction %^a

53.23 (± 11.98)

52.5 (47 – 63)

51.81 (± 11.25)

53.5 (41.5 – 60)

50.74 (± 9.38)

51 (43 – 59)

0.6

Myocardial Wall Motion Score Index^a

1.379 (± 0.36)

1.25 (1.13 – 1.5)

1.436 (± 0.29)

1.375 (1.25 – 1.75)

1.448 (± 0.37)

1.375 (1.19 – 1.75)

0.3

In-Hospital GRACE Score^a

157.41 (± 35.21)

150 (136.75 – 175.25)

149.12 (± 25.48)

148.5 (129 – 167.5)

142.87 (± 27.85)

139 (123 – 156)

0.07

Post-Discharge GRACE Score^a

123.82 (± 27.1)

120 (105 – 141)

116.75 (± 20.03)

118 (102.25 – 129)

110.23 (± 27.02)

106 (91 – 124)

0.03*

Total CK on Admission^a

1211.64 (± 1823.93)

611 (217 – 1488)

1436.94 (± 1673.42)

664.5 (298 – 2236.75)

1485.41 (± 1986.43)

548 (172.5 – 2168)

0.7

Peak CK value^a

1542.54 (± 1852.77)

1145 (552 – 1930)

1923.75 (± 2042.19)

1189 (363.75 – 2828)

1893.49 (± 2128.73)

1220 (287 – 2560)

0.9

CK-MB on Admission^a

188.02 (± 287.06)

94 (40.5 – 200)

192.34 (± 296.36)

115 (38.5 – 281)

168.68 (± 207.09)

79 (37.25 – 241.75)

0.9

Peak CK-MB value^a

223.41 (± 289.12)

128 (71.5 – 270.5)

239.88 (± 311.63)

150.5 (62.75 – 334)

193.48 (± 206.95)

116.5 (52.5 – 277.5)

0.7

Troponin^a

19.861 (± 36.72)

4.65 (0.77 – 23.75)

11.696 (± 17.46)

3.8 (0.36 – 16.5)

9.012 (± 16.07)

1.59 (0.3 – 9.6)

0.6

S. Urea on Admission^a

6.1932 (± 3.11)

5 (4.13 – 7)

6.345 (± 3.02)

6 (5 – 7)

5.824 (± 2.52)

5 (4 – 7)

0.5

S. Creatinine on Admission^a

1.101 (± 0.73)

0.91 (0.7 – 1.3)

0.924 (± 0.27)

0.9 (0.8 – 1.09)

0.893 (± 0.25)

0.9 (0.7 – 1.1)

0.3

Creatinine Clearance^a

82.38 (± 34.55)

88.5 (51.75 – 107)

101.44 (± 33.36)

101 (80 – 129.75)

103.72 (± 29.45)

101.5 (85.5 – 118.75)

0.016*

Dominance^b

Right: 46 (95.8%)

Left: 2 (4.2%)

Right: 44 (84.6%)

Left: 8 (15.4%)

Right: 46 (93.9%)

Left: 3 (6.1%)

0.1

Number of Initial Lesions^a

3.88 (± 1.58)

3 (3 – 4.75)

3.04 (± 1.08)

3 (2 – 4)

2.39 (± 0.67)

2 (2 – 3)

< 0.001*

Number of Residual Lesions^a

3.13 (± 1.59)

1.96 (± 0.86)

0.53 (± 0.54)

< 0.001*

Culprit Vessel^b

RCA: 30 (62.5%)

LM: 1 (2.1%)

LAD: 11 (22.9%)

LCx: 6 (12.5%)

RCA: 14 (26.9%)

LM: 0 (0%)

LAD: 27 (51.9%)

LCx: 11 (21.2%)

RCA: 8 (16.3%)

LM: 1 (2%)

LAD: 34 (69.4%)

LCx: 6 (12.2%)

< 0.001*

Baseline Culprit TIMI Flow^b

0-1: 29 (60.4%)

2-3: 19 (39.6%)

0-1: 37 (71.2%)

2-3: 15 (28.8%)

0-1: 29 (59.2%)

2-3: 20 (40.8%)

0.4

Post-procedural Culprit TIMI Flow^b

0-1: 4 (8.3%)

2-3: 44 (91.7%)

2-3: 52 (100%)

2-3: 49 (100%)

0.01*

Cases with LMCA Lesions^b

7 (14.6%)

1 (1.9%)

1 (2%)

0.009*

Proximal RCA^b

25 (52.1%)

18 (34.6%)

12 (24.5%)

0.017*

Proximal LAD^b

21 (43.8%)

23 (44.2%)

25 (51%)

0.7

Proximal LCx^b

24 (50%)

21 (40.4%)

12 (24.5%)

0.033*

Staged PCI^b

2 (4.2%)

10 (19.2%)

18 (36.7%)

< 0.001*

Interval Between PCI Sessions in Months^a

3.5 (± 0.71)

6.9 (± 3.73)

4.083 (± 3.06)

0.1

bSS^a

28 (± 13.28)

25.25 (18.63 – 31)

23.183 (± 9.47)

24 (15.5 – 29)

19.776 (± 6.35)

19 (15.5 – 23.75)

0.003*

rSS^a

21.219 (± 12.2)

17 (12.13 – 25.75)

8.808 (± 4.66)

8.5 (5.25 – 11.75)

1.52 (± 1.93)

1 (0 – 3)

< 0.001*

Number of Stents Used^a

1.44 (± 0.74)

1.92 (± 1.1)

2.16 (± 0.87)

0.002*

In-Hospital Composite MACE^b

5 (10.4%)

8 (15.4%)

9 (18.4%)

0.5

In-Hospital Heart Failure^b

2 (4.2%)

4 (7.7%)

7 (14.3%)

0.2

In-Hospital Non-fatal MI^b

1 (2.1%)

0 (0%)

0 (0%)

0.3

In-Hospital TLR^b

1 (2.1%)

0 (0%)

0 (0%)

0.3

In-Hospital Death^b

4 (8.3%)

1 (1.9%)

2 (4.1%)

0.2

In-Hospital Bleeding^b

0 (0%)

0 (0%)

1 (2%)

0.7

Acute Kidney Injury^b

3 (6.3%)

2 (3.8%)

6 (12.2%)

0.3

Variable

1st SRI Tertile

(≤ 47.06)

(n = 40)

2nd SRI Tertile

(47.06–78.18)

(n = 35)

3rd SRI Tertile

(> 78.18)

(n = 39)

P value

Follow-Up Cumulative MACE^b

17 (42.5%)

10 (28.6%)

12 (30.8%)

0.4

Death^b

13 (32.5%)

5 (14.3%)

5 (12.8%)

0.054

Non-fatal MI^b

5 (12.5%)

2 (5.7%)

1 (2.6%)

0.2

TLR^b

2 (5%)

3 (8.6%)

5 (12.8%)

0.4

Heart Failure^b

3 (7.5%)

6 (17.1%)

4 (10.3%)

0.4